Alaunos shares jump 12.65% intraday after terminating Cantor Fitzgerald advisory engagement.

Alaunos Therapeutics, Inc. (TCRT) surged 12.65% intraday following its announcement to terminate the exclusive advisory engagement with Cantor Fitzgerald. The move, disclosed via an SEC filing, aligns with broader governance updates, suggesting a strategic shift to streamline operations or reduce costs. While such terminations can sometimes signal challenges, the market appeared to interpret the decision positively, potentially viewing it as a step toward improved corporate efficiency or reallocation of resources. Other news, including a Russian-language corporate action cancellation and unrelated Yahoo Finance errors, held no material relevance to the stock’s sharp intraday rally.